Balyasny Asset Management
RVNC

Balyasny Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Balyasny Asset Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-96,154
Closed -$419K – 3374
2024
Q3 		$499K Buy
+96,154
New +$478K ﹤0.01% 2254
2024
Q1 		– Sell
-362,760
Closed -$3.19M – 3216
2023
Q4 		$3.19M Sell
362,760
-107,089
-23% -$877K 0.01% 1294
2023
Q3 		$5.39M Buy
+469,849
New +$9.03M 0.01% 1078
2018
Q4 		– Sell
-8,262
Closed -$205K – 1836
2018
Q3 		$205K Sell
8,262
-3,106
-27% -$84.5K ﹤0.01% 1584
2018
Q2 		$312K Buy
+11,368
New +$342K ﹤0.01% 1504
2016
Q1 		– Sell
-7,630
Closed -$261K – 1573
2015
Q4 		$261K Sell
7,630
-4,120
-35% -$143K ﹤0.01% 1011
2015
Q3 		$350K Buy
+11,750
New +$357K ﹤0.01% 880
2015
Q2 		– Sell
-80,323
Closed -$1.67M – 1366
2015
Q1 		$1.67M Buy
+80,323
New +$1.39M 0.01% 652

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Balyasny Asset Management's RVNC Position: Q4 2024 in Review

Balyasny Asset Management sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 96,154 shares — an estimated $419K sold.

Balyasny Asset Management first reported a position in RVNC in Q1 2015 and held it in 8 quarters. The position peaked at $5.39M in Q3 2023. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

  • Balyasny Asset Management reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 96,154 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $419K.
  • Balyasny Asset Management first reported a position in Revance Therapeutics, Inc. in Q1 2015 and held it in 8 quarters.
  • Balyasny Asset Management's Revance Therapeutics, Inc. position peaked at $5.39M in Q3 2023.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on Balyasny Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.